XDx Says Lack of Financial Incentives Blocking Physician Uptake of Heart Transplant Rejection Test

Despite having published validation studies, garnered cost-effectiveness data, received FDA approval, and gotten payor coverage for AlloMap, XDx hasn't seen the level of adoption it expected for the gene-expression-based transplant-rejection test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.